Chile defends Sinovac use amid fresh efficacy questions

Chile defends Sinovac use amid fresh efficacy questions
Chile defends Sinovac use amid fresh efficacy questions

Hello and welcome to the details of Chile defends Sinovac use amid fresh efficacy questions and now with the details

Nevin Al Sukari - Sana'a - A medical worker takes a box of Sinovac’s vaccine against the coronavirus disease from a refrigerator at a community health centre in Qingdao, Shandong province, China January 5, 2021. — China Daily pic via Reuters

Subscribe to our Telegram channel for the latest updates on news you need to know.


SANTIAGO, April 12 — Chilean authorities yesterday backed the country’s widespread use of the Covid-19 vaccine manufactured by Chinese firm Sinovac after China’s top disease official appeared to make conflicting statements about its efficacy.

Gao Fu, the director of the Chinese Centers for Disease Control and Prevention, told a conference in the Chinese city of Chengdu on Saturday that the country was considering mixing Covid-19 vaccines since currently available vaccines “don’t have very high rates of protection.”

He later said in an interview with state that his comments were “completely misunderstood.”

Available data shows Chinese vaccines lag behind others including Pfizer and Moderna in terms of efficacy, but require less stringent temperature controls during storage.

The Covid-19 vaccine developed by China’s Sinovac was found to be just over 50 per cent effective in reducing infection in Brazilian clinical trials. A real-world study of vaccination and contagion data by the University of Chile suggested last week the vaccine was 54 per cent effective in reducing infection.

Chile paid US$3.5 million (RM14.5 million) to host a clinical trial of the vaccine and has also ordered 60 million doses to be administered to its 18 million-strong population over three years.

The country has largely relied on the Sinovac vaccine, along with smaller numbers of Pfizer’s equivalent drug, to roll out one of the world’s fastest vaccination campaigns, so far inoculating 4.6 million people with two doses and 7.2 million with one.

Chile also signed deals for the supply of vaccines from western drugmakers Johnson & Johnson and AstraZeneca but these are yet to materialise because of supply bottlenecks.

Yesterday, Chilean science minister Andres Couve said it was important to focus on the data and the vaccine’s effectiveness in reducing illness that required medical treatment or being hospitalised or dying, which it achieved in the Brazilian study in 83.7 per cent and 100 per cent of cases respectively.

He said Chile’s health ministry will shortly publish a real world study on the effectiveness of both vaccines rolled out in its population and appealed to Chileans to continue to participate in the vaccination programme.

Heriberto Garcia, director of Chile’s Public Health Institute which greenlighted CoronaVac’s emergency roll-out, said people should not pay attention to headlines.

“The University of Chile study and the study the health ministry will release say the same thing: The number of people who fall ill and are hospitalised has decreased,” he told local newspaper La Tercera. “We are going down the right path.” — Reuters

These were the details of the news Chile defends Sinovac use amid fresh efficacy questions for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV US CDC finds more clotting cases after J&J vaccine, sees causal link
NEXT India's lauds Gulf assistance in fighting COVID-19